|Bid||0.6122 x 2200|
|Ask||0.6300 x 1000|
|Day's Range||0.5962 - 0.6300|
|52 Week Range||0.5940 - 1.8900|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||15.25|
|Earnings Date||Nov 08, 2022 - Nov 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.38|
By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Second Quarter 2022 Financial and Operational Results On August 8, 2022 Lipocine (NASDAQ:LPCN) filed its second quarter 2022 Form 10-Q and posted its earnings release for the quarter ending June 30, 2022. Highlights for the second quarter 2022 and to-date include: ➢ New board of director appointments – April 2022 ➢ LPCN 1144
Lipocine (NASDAQ:LPCN) has had a rough week with its share price down 7.1%. But if you pay close attention, you might...
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products to treat metabolic and central nervous system ("CNS") disorders, today announced financial results for the second quarter ended June 30, 2022 and provided a corporate update.